186 related articles for article (PubMed ID: 33770461)
1. Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer.
Mamdani H; Jalal SI
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-16. PubMed ID: 33770461
[TBL] [Abstract][Full Text] [Related]
2. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
Zhao D; Klempner SJ; Chao J
J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of gastroesophageal junction cancer.
Greally M; Agarwal R; Ilson DH
Cancer; 2019 Jun; 125(12):1990-2001. PubMed ID: 30973648
[TBL] [Abstract][Full Text] [Related]
5. Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.
Cetin B; Wabl CA; Gumusay O
Immunotherapy; 2023 Aug; 15(12):945-962. PubMed ID: 37291863
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic targets on cancer therapy in esophagogastric cancer.
Jiang Y
Adv Exp Med Biol; 2013; 779():55-65. PubMed ID: 23288635
[TBL] [Abstract][Full Text] [Related]
7. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
8. Novel Targeted Therapies for Esophagogastric Cancer.
Maron SB; Catenacci DV
Surg Oncol Clin N Am; 2017 Apr; 26(2):293-312. PubMed ID: 28279470
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Bockorny B; Pectasides E
Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
[TBL] [Abstract][Full Text] [Related]
10. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.
Ilhan-Mutlu A; Taghizadeh H; Beer A; Dolak W; Ba-Ssalamah A; Schoppmann SF; Hejna M; Birner P; Preusser M
Cancer Biol Ther; 2018 Mar; 19(3):169-174. PubMed ID: 29252101
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies for metastatic esophagogastric cancer.
Reddy D; Wainberg ZA
Curr Treat Options Oncol; 2011 Mar; 12(1):46-60. PubMed ID: 21298375
[TBL] [Abstract][Full Text] [Related]
12. Targeting the human EGFR family in esophagogastric cancer.
Okines A; Cunningham D; Chau I
Nat Rev Clin Oncol; 2011 Apr; 8(8):492-503. PubMed ID: 21468131
[TBL] [Abstract][Full Text] [Related]
13. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in immune-based approaches for the treatment of esophagogastric cancer.
Weadick CS; Duffy AG; Kelly RJ
Expert Opin Emerg Drugs; 2022 Mar; 27(1):19-31. PubMed ID: 34937483
[TBL] [Abstract][Full Text] [Related]
15. Targeted Treatment of Esophagogastric Cancer.
Kopp HG; Hofheinz RD
Oncol Res Treat; 2016; 39(12):788-794. PubMed ID: 27889780
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
17. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
[TBL] [Abstract][Full Text] [Related]
18. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.
Nagaraja AK; Kikuchi O; Bass AJ
Cancer Discov; 2019 Dec; 9(12):1656-1672. PubMed ID: 31727671
[TBL] [Abstract][Full Text] [Related]
19. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Janjigian YY; Sanchez-Vega F; Jonsson P; Chatila WK; Hechtman JF; Ku GY; Riches JC; Tuvy Y; Kundra R; Bouvier N; Vakiani E; Gao J; Heins ZJ; Gross BE; Kelsen DP; Zhang L; Strong VE; Schattner M; Gerdes H; Coit DG; Bains M; Stadler ZK; Rusch VW; Jones DR; Molena D; Shia J; Robson ME; Capanu M; Middha S; Zehir A; Hyman DM; Scaltriti M; Ladanyi M; Rosen N; Ilson DH; Berger MF; Tang L; Taylor BS; Solit DB; Schultz N
Cancer Discov; 2018 Jan; 8(1):49-58. PubMed ID: 29122777
[TBL] [Abstract][Full Text] [Related]
20. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
